地拉罗司对铁质积聚的疗效

Developed by Novartis and currently the only oral iron chelator, deferasirox was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. Deferasirox was approved by the European Commission in December 2012. Deferasirox is used to treat chronic iron overload in patients aged 10 and above with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy. Deferasirox is a commonly used drug to relieve iron accumulation.

According to a retrospective study in Italy, 42.7% of patients achieved a hematological response and reduced the need for blood transfusions after receiving DFO or deferasirox chelation therapy. There may be a dynamic, bidirectional regulatory mechanism between erythropoiesis and iron overload. On the one hand, ineffective erythropoiesis can lead to increased intestinal iron absorption through reduced hepcidin secretion by the liver. On the other hand, chelation treatment of iron overload can improve erythropoiesis, increase hemoglobin levels, and reduce clinical blood transfusions.

The results of a single-arm, multi-center, prospective clinical study enrolling 64 AA patients with transfusion-related iron overload confirmed the effectiveness and safety of deferasirox in reducing patients' ferritin levels. A prospective, observational study in my country using liver, pancreas, and heart as monitoring indicators confirmed that deferasirox can improve organ function in patients with iron overload. The TELESTO study results released at ASH2018 also proved that deferasirox continuously reduces serum ferritin levels, while reducing the risk of heart function damage, liver function damage, transformation to leukemia and other events by 36.4%.

The above is an introduction to the efficacy of iron accumulation. For more information about deferasirox, please contact Medical Companion Travel for details.